Diabetes mellitus (DM) is a world health problem of global repercussion. It is expected that, in the next 20 years, the number of patients with DM will increase to 642 million people [1]. Type 1 diabetes mellitus (T1DM) responds to a multifactorial pathogenesis essentially linked to an autoimmune aggression mediated by T cells and autoantibodies that generate a progressive loss of insulin producing cells in the pancreas [2]. On the other hand, the pathogenesis of type 2 diabetes mellitus (T2DM) is essentially linked to the development of a state of resistance to the actions of insulin [3]. Both types are the consequence of an interaction of environmental, epigenetic, and genetic factors [4]. Genetic factors promote a special susceptibility to the development of the disease and epigenetics is considered as the link between the environment and genetics, altering gene and protein expression that could affect in autoimmunity and in the vulnerability of beta cells of pancreatic islets to the external factors.

In fact, clinical practice guidelines state that good metabolic—glycemic—control contributes to the reduction of complications associated with T1DM [5] and with T2DM [6] and that the best parameter to define the degree of glycemic control is glycosylated hemoglobin (HbA1c) which provides the average blood glucose levels in the last 2–3 months [5,6]. In addition, the development of new technologies to improve the management of DM, such as continuous glucose monitoring systems (CGMS) that measure glucose in interstitial fluid, show that they are the best way to monitor glucose levels to avoid hypoglycemia and to reduce glucose excursions. In fact, different studies have shown that these devices significantly reduce the number and intensity of hypoglycemia and improve HbA1c levels in both T1DM [7] and T2DM patients receiving insulin therapy [8].

However, the main challenge to clinicians is to reduce morbidity and mortality linked to DM, since complications associated with DM progression can arise both in the short and long term of the disease evolution. Hyperglycemia is a frequent finding in both hospitalized [9] and outpatients [10] and the management of glucose levels is the target on the most clinical trials. The use of modern insulin pumps offer a great variety of possibilities to which is added the incorporation of sensors-augmented insulin-pump, thus allowing its regulation and a higher and better level of safety in the device [11]. In T2DM, the treatment with non-insulin agents [12] contributes to improve the efficiency of insulin on glycemia levels and reflects the need to find a specific and personalized therapies for the profile of each patient. Actually, there is an increasing need to identify and provide evidence about the efficiency and safety of new therapy modalities and some of them have been included in this Special Issue.

DM is a life-threatening disease that causes complications and is considered as a serious disorder that doubles the risk of premature death [13]. Some aspects related with different fields into the DM progression have also been addressed in this Special Issue, such as the obstructive sleep apnea due to hypoxia implications [14], microvascular [15] and macrovascular [16] complications, elevated low-density lipoprotein (LDL) and cholesterol [17], and different oral processes [18]. A specifically complication associated with
gestational diabetes mellitus (GDM) is the increased risk of hypertensive disorders; in this regard, new models based on biomarker parameters allow us to detect patients with GDM and these disorders and start earlier preventive strategies [19].

Upon the improvement of DM management, the scientific knowledge of the different underlying processes is very important. The implication of molecular mechanisms that could justify an adequate treatment option or the optimal technologies for an early diagnosis have to be included into the structural organigram of the study and follow-up of DM. The potential new biochemical targets, such as IL-1 in T1DM [20] or insulin receptor in T2DM [21], involve a deep analysis of the intracellular signaling and its potential implication in the physiopathology of the disease.

The prevention of complications of DM is relevant and requires an early diagnosis together with adequate treatment and follow-up of the patient. The most effective preventive strategy to avoid and/or delay the onset and development of DM complications is early diagnosis and early intervention aimed at mitigating symptoms and reducing sequelae and costs.

**Author Contributions:** Writing—original draft preparation, M.A.-D. and A.I.A.; writing—review and editing, M.A.-D. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. IDF Diabetes Atlas. 2022 International Diabetes Federation. Available online: https://diabetesatlas.org/ (accessed on 21 August 2022).
2. Gillespie, K.M. Type 1 diabetes: Pathogenesis and prevention. *Can. Med. Assoc. J.* 2006, 175, 165–170. [CrossRef] [PubMed]
3. DeFronzo, R.A. Pathogenesis of type 2 diabetes mellitus. *Med. Clin. N. Am.* 2004, 88, 787–835. [CrossRef] [PubMed]
4. Diedesheim, M.; Carcarino, E.; Vandiedonck, C.; Roussel, R.; Gautier, J.-F.; Venteclef, N. Regulation of inflammation in diabetes: From genetics to epigenomics evidence. *Mol. Metab.* 2020, 41, 101041. [CrossRef] [PubMed]
5. Nathan, D.M.; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. *Diabetes Care* 2014, 37, 9–16. [CrossRef] [PubMed]
6. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998, 352, 837–853. [CrossRef]
7. Bolinder, J.; Antuna, R.; Geelhoed-Duijvestijn, P.; Kröger, J.; Weitgasser, R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non-masked, randomised controlled trial. *Lancet* 2016, 388, 2254–2263. [CrossRef]
8. Benn, E.; García, E.; Carreño, E.; Gutiérrez, M.; Balmaceda, S.; Dalmases, F.; Ibarguren, E.; et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. *Ann. Int. Med.* 2017, 167, 365–374. [CrossRef] [PubMed]
9. Kodner, C.; Anderson, L.; Pohligers, K. Glucose Management in Hospitalized Patients. *Am. Fam. Physician* 2017, 96, 648–654. [PubMed]
10. Rubin, D.J.; Shah, A.A. Predicting and Preventing Acute Care Re-Utilization by Patients with Diabetes. *Curr. Diab. Rep.* 2021, 21, 34. [CrossRef] [PubMed]
11. Bergenstal, R.M.; Tamborlane, W.V.; Ahmann, A.; Buse, J.B.; Dailey, G.; Davis, S.N.; Joyce, C.; Peoples, T.; Perkins, B.A.; Welsh, J.B.; et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *N. Engl. J. Med.* 2010, 363, 311–320. [CrossRef] [PubMed]
12. Siegel, K.R.; Ali, M.K.; Zhou, X.; Ng, B.P.; Jawanda, S.; Proia, K.; Zhang, X.; Gregg, E.W.; Albright, A.L.; Zhang, P. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008? *Diabetes Care* 2020, 43, 1557–1592. [CrossRef] [PubMed]
13. World Health Organization. Global Health Estimates (2000–2019). Available online: https://www.who.int/data/global-health-estimates (accessed on 21 August 2022).
14. Sánchez, E.; Sapina-Beltrán, E.; Gavaldà, R.; Barbé, F.; Torres, G.; Sauret, A.; Dalmases, M.; López-Cano, C.; Gutiérrez-Carrascoilla, L.; Bermúdez-López, M.; et al. Prediabetes is Associated with Increased Prevalence of Sleep-Disordered Breathing. *J. Clin. Med.* 2022, 4, 1413. [CrossRef] [PubMed]
15. Jimenez-Carmona, S.; Alemany-Marquez, P.; Alvarez-Ramos, P.; Mayoral, E.; Aguilar-Diosdado, M. Validation of an Automated Screening System for Diabetic Retinopathy Operating under Real Clinical Conditions. *J. Clin. Med.* 2022, 11, 14. [CrossRef] [PubMed]
16. Gómez-Perez, A.M.; Damas-Fuentes, M.; Cornejo-Pareja, I.; Tinhones, F.J. Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. *J. Clin. Med.* 2021, 10, 4497. [CrossRef] [PubMed]
17. Funakoshi, S.; Maeda, T.; Yoshimura, C.; Kawazoe, M.; Satoh, A.; Yokota, S.; Tada, K.; Takahashi, K.; Kenji Ito, K.; Yasuno, T.; et al. Effects of Weight Gain after 20 Years of Age and Incidence of Hyper-Low-Density Lipoprotein Cholesterolemia: The Iki Epidemiological Study of Atherosclerosis and Chronic Kidney Disease (ISSA-CKD). *J. Clin. Med.* **2021**, *10*, 3098.

18. González-Moles, M.A.; Ramos-García, P. State of Evidence on Oral Health Problems in Diabetic Patients: A Critical Review of the Literature. *J. Clin. Med.* **2021**, *10*, 5383. [CrossRef] [PubMed]

19. Lara-Barea, A.; Sánchez-Lechuga, B.; Campos-Caro, A.; Córdoba-Doña, J.A.; de la Varga-Martínez, R.; Arroba, A.I.; Bugatto, F.; Aguilar-Diosdado, M.; López-Tinoco, C. Angiogenic Imbalance and Inflammatory Biomarkers in the Prediction of Hypertension as Well as Obstetric and Perinatal Complications in Women with Gestational Diabetes Mellitus. *J. Clin. Med.* **2022**, *11*, 1514. [CrossRef] [PubMed]

20. Cano-Cano, F.; Gómez-Jaramillo, L.; Ramos-García, P.; Arroba, A.I.; Aguilar-Diosdado, M. IL-1 Implications in Type 1 Diabetes Mellitus Progression: Systematic Review and Meta-Analysis. *J. Clin. Med.* **2022**, *11*, 1303. [CrossRef] [PubMed]

21. Mkrtumyan, A.; Ametov, A.; Demidova, T.; Volkova, A.; Dudinskaya, E.; Vertkin, A.; Vorobiev, S. A New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta. *J. Clin. Med.* **2022**, *11*, 1390. [CrossRef] [PubMed]